Review | Published:

Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine

Acta Pharmacologica Sinica volume 27, pages 126 (2006) | Download Citation

Project supported in part by the grants from Ministry of Science and Technology of China (G1998051110, G1998051115, 2004CB518907) and the National Natural Science Foundation of China (No 39170860, 39770846, 3001161954, 30123005, 30271496, and 30572169).

Subjects

Abstract

Huperzine A (HupA), a novel alkaloid isolated from the Chinese herb Huperzia serrata, is a potent, highly specific and reversible inhibitor of acetylcholinesterase (AChE). Compared with tacrine, donepezil, and rivastigmine, HupA has better penetration through the blood-brain barrier, higher oral bioavailability, and longer duration of AChE inhibitory action. HupA has been found to improve cognitive deficits in a broad range of animal models. HupA possesses the ability to protect cells against hydrogen peroxide, β-amyloid protein (or peptide), glutamate, ischemia and staurosporine-induced cytotoxicity and apoptosis. These protective effects are related to its ability to attenuate oxidative stress, regulate the expression of apoptotic proteins Bcl-2, Bax, P53, and caspase-3, protect mitochondria, upregulate nerve growth factor and its receptors, and interfere with amyloid precursor protein metabolism. Antagonizing effects of HupA on N-methyl-D-aspartate receptors and potassium currents may also contribute to its neuroprotection as well. Pharmacokinetic studies in rodents, canines, and healthy human volunteers indicated that HupA was absorbed rapidly, distributed widely in the body, and eliminated at a moderate rate with the property of slow and prolonged release after oral administration. Animal and clinical safety tests showed that HupA had no unexpected toxicity, particularly the dose-limiting hepatotoxicity induced by tacrine. The phase IV clinical trials in China have demonstrated that HupA significantly improved memory deficits in elderly people with benign senescent forgetfulness, and patients with Alzheimer disease and vascular dementia, with minimal peripheral cholinergic side effects and no unexpected toxicity. HupA can also be used as a protective agent against organophosphate intoxication.

References

  1. 1.

    , , , . The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–14.

  2. 2.

    , , , , , . Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2: 1457–9.

  3. 3.

    . Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int 1998; 32: 413–9.

  4. 4.

    . Introduction to cholinesterase inhibitors used in Alzheimer's disease therapy. In: , editors Alzheimer's disease: therapeutic strategies. Boston: Birkhäuser; 1994. p 99–102.

  5. 5.

    . Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc 2005; 105: 145–58.

  6. 6.

    , , . A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 2005; 26: 104–11.

  7. 7.

    , , , , , . A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523–9.

  8. 8.

    , , , , , . A 30–week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985–91.

  9. 9.

    , , , , . A 24–week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136–45.

  10. 10.

    , . Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 1998; 349: 137–42.

  11. 11.

    , , . Anticholinesterase activity of huperzine A. Acta Pharmacol Sin 1986; 7: 110–3. Chinese.

  12. 12.

    , . Effects of huperzine A on acetylcholinest-erase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J Pharmacol 2002; 455: 101–7.

  13. 13.

    , . Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci Lett 2004; 361: 56–9.

  14. 14.

    , , , , , et al. Efficacy of tablet huperzine A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacol Sin 1995; 16: 391–5.

  15. 15.

    , , , , , et al. Efficacy of tablet huperzine A on memory and cognition in patients with benign senescent forgetfulness. Chin J Clin Pharmacol Ther 1997; 2: 1–4. Chinese.

  16. 16.

    , , , , , . Huperzine A in capsules and tablets for treating patients with Alzheimer's disease. Acta Pharmacol Sin 1999; 20: 486–90.

  17. 17.

    , , , , , . Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Natl Med J China 2002; 82: 941–4. ( Chinese).

  18. 18.

    , , , . A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88–95.

  19. 19.

    , . Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Acta Pharmacol Sin 1998; 19: 27–30.

  20. 20.

    , , . Effects of huperzine A on the cognition and daily life ability in vascular dementia: 36 cases for 6 months follow-up study. Chin J Clin Rehabil 2004; 8: 3892. Chinese.

  21. 21.

    , , , . Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Clin Pharmacol 2000; 22: 609–13.

  22. 22.

    , , . Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuoreport 1996; 8: 97–101.

  23. 23.

    , . The inhibitory characteristics of fordine on cholinesterases. Bull Acad Mil Med Sci 1986; 10: 451–6. Chinese.

  24. 24.

    , , . Effects of huperzine A on cholinesterase isoenzymes in plasma of mice and dogs. Acta Pharmacol Sin 1988; 9: 312–6. Chinese.

  25. 25.

    , , , , , . Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons. Exp Neurol 2004; 188: 461–70.

  26. 26.

    , . Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1998; 60: 377–86.

  27. 27.

    . Molecular forms of acetylcholinesterase in brain, nerve and muscle: nature, localization and dynamics. Prog Neurobiol 1983; 21: 291–322.

  28. 28.

    , . The molecular forms of cholinesterase and acetylcholinesterase invertebrate. Annu Rev Neurosci 1982; 5: 57–106.

  29. 29.

    , , . Asymmetric and globular forms of AChE in mammals and birds. Proc Natl Acad Sci USA 1979; 76: 2540–50.

  30. 30.

    , , . Molecular forms of acetylcholinesterase in bovine caudate nucleus and superior cervical ganglion: solubility properties and hydrophobic character. J Neurochem 1982; 387: 457–69.

  31. 31.

    , , , . Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989; 24: 276–85.

  32. 32.

    , , , . Comparison of the effects of natural and synthetic huperzine A on rat brain cholinergic function in vitro and in vivo. J Ethnopharmacol 1994; 44: 147–55.

  33. 33.

    , , , , . Acute and chronic studies with the anticholinesterase huperzine A: Effect on central nervous system cholinergic parameters. Neuropharmacology 1991; 30: 763–8.

  34. 34.

    , , , , . Stereoselectivities of enantiomers of huperzine A in protection against beta amyloid 25–35–induced injury in PC12 and NG108–15 cells and cholinesterase inhibition in mice. Neurosci Lett 2002; 317: 143–6.

  35. 35.

    , , , , , . Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Strut Biol 1997; 4: 57–63.

  36. 36.

    , , , , , et al. X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. Biochemistry 2002; 41: 10810–8.

  37. 37.

    , , . Mechanism of inhibition of cholinesterase by huperzine A. Biochem Biophys Res Commun 1992; 184: 7719–26.

  38. 38.

    , . Prediction of the bonding site of huperzine A in acetylcholinesterase by docking studies. J Computer Aided Mol Des 1994; 8: 669–81.

  39. 39.

    . Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy. JAMA 1997; 277: 776.

  40. 40.

    , , , , , et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993; 90: 9031–5.

  41. 41.

    , , , , , et al. Identification of amino acid residues involved in the binding of huperzine A to cholinesterase. Protein Sci 1994; 3: 1770–8.

  42. 42.

    , , , , , et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253: 872–9.

  43. 43.

    , , . Facilitatory effect of huperzine A on mouse neuromuscular transmission in vitro. Acta Pharmacol Sin 1996; 17: 299–301.

  44. 44.

    , , . Comparison between huperzine A, tacrine and E2020 on cholinergic transmission at mouse neuromuscular junction in vitro. Acta Pharmacol Sin 1997; 18: 6–10.

  45. 45.

    , , , . Facilitation of cholinergic transmission by huperzine A in toad paravertebral ganglia in vitro. Acta Pharmacol Sin 1994; 15: 158–61.

  46. 46.

    , , . Facilitation and inhibition of nicotine transmission by eserine in the sympathetic ganglia of the rabbit. Neuropharmacology 1985; 24: 1093–101.

  47. 47.

    . Enhancement and depression of cholinergic transmission by 9–amino-1,2,3,4–tetrahydroacridine in rat superior cervical ganglia. Chin Pharmacol Bull 1993; 9: 298–300. Chinese.

  48. 48.

    , . Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons. Mol Pharmacol 2004; 66: 658–66.

  49. 49.

    , , , . Effects of huperzine A and B on skeletal muscle and electroencephalogram. Acta Pharmacol Sin 1987; 8: 117–23. Chinese.

  50. 50.

    , , , , . The effect of huperzine A on behavior and ECoG in animals. Acta Psychol Sin 1991; 23: 404–11.

  51. 51.

    , , , . The effect of huperzine Aon behavior and ECoG in animals. Acta Pharmacol Sin 1991; 12: 496–500. Chinese.

  52. 52.

    , , . Potentiation of acetylcholine action by huperzine-A and physostigmine on some vertebrate effectors, including human iris sphincter muscle. J Ocul Pharmacol Ther 2003; 19: 135–43.

  53. 53.

    , , , , . The effect of heptylphysostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat. Neurochem Res 1989; 14: 971–7.

  54. 54.

    , , , , . Effect of THA on acetylcholine release and cholinergic receptor in Alzheimer brains. In: , editors Current research in Alzheimer therapy. New York: Taylor and Francis; 1988. p 247–58.

  55. 55.

    , . Physostigmine, tacrine and metrifonate. The effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989; 28: 199–206.

  56. 56.

    , . Second generation cholinesterase inhibitors: effect of (L)-huperzine A on cortical biogenic amines. J Neurosci Res 1995; 41: 828–35.

  57. 57.

    , , , , , et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 1983; 41: 266–72.

  58. 58.

    , , . Improving effect of huperzine A on discrimination performance in aged rats and adult rats with experimental cognitive impairment. Acta Pharmacol Sin 1988; 9: 11–5. Chinese.

  59. 59.

    , , , . Effects of huperzine A on learning and retrieval process of discrimination performance in rats. Acta Pharmacol Sin 1986; 7: 507–11. Chinese.

  60. 60.

    , . Facilitatory effects of huperzine A and B on learning and memory of spatial discrimination in mice. Acta Pharmacol Sin 1987; 22: 812–7. Chinese.

  61. 61.

    , . Improvement of impaired memory in mice by huperzine A and huperzine B. Acta Pharmacol Sin 1988; 9: 492–7. Chinese.

  62. 62.

    , , , . Huperzine A reverses scopolamine- and muscimol-induced memory deficits in chick. Acta Pharmocol Sin 2000; 21: 1169–73.

  63. 63.

    , , , , , . Effects of synthetic (-)-huperzine A on cholinesterase activities and mouse water maze performance. Acta Pharmacol Sin 1998; 19: 413–6.

  64. 64.

    , , , . Huperzine A ameliorates the impaired memory of aged rat in the Morris water maze performance. Acta Pharmacol Sin 2000; 21: 65–9.

  65. 65.

    , . Effect of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Pharmacol Biochem Behav 1995; 51: 415–9.

  66. 66.

    , , , . Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther 1999; 288: 814–9.

  67. 67.

    , , . Effect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys. Eur J Pharmacol 2001; 433: 151–6.

  68. 68.

    , , , , . The effects of huperzine A, an acetylcholinesterase inhibitor, on the enhancement of memory in mice, rats and monkeys. Neurosci Abs 1987; 13: 844.

  69. 69.

    , , . Huperzine A ameliorates the spatial working memory impairments induced by AF64A. Neuroreport 1995; 6: 2221–4.

  70. 70.

    , , , , . Protective effect of tetramethylpyrazine on learning and memory function in D-galactose-lesioned mice. Chin Med Sci J 2004; 19: 180–4.

  71. 71.

    , , , , . Cognitive improvement by oral huperzine A: a novel acetylcholinesterase inhibitor. In: , editors Alzheimer therapy: therapeutic strategies. Boston: Birkhäuser; 1994. p 113–9.

  72. 72.

    , , . Effects of huperzine A on nucleus basalis magnocellularis lesion-induced spatial working memory deficit. Acta Pharmacol Sin 1998; 19: 128–32.

  73. 73.

    , , . Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983; 219: 1184–90.

  74. 74.

    , . Modulation of memory by benzodiaz-epineacetylcholine interactions. In: , , editors Neurotransmitter interactions and cognitive function. Boston: Birkhäuser; 1992. p 312–28.

  75. 75.

    , , , , . Aged-related changes in multiple neurotransmitter systems in the monkey brain. Neurobiol Aging 1989; 10: 11–9.

  76. 76.

    , , . Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1–40) in rat. Eur J Pharmacol 2001; 21: 149–56.

  77. 77.

    , . A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993; 361: 31–9.

  78. 78.

    , , , . NMD A receptors: from genes to channels. Trends Pharmacol Sci 1996; 17: 348–55.

  79. 79.

    , , , . Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 2000; 60: 65–72.

  80. 80.

    , . Suppressive action produced by beta-amyloid peptide fragment 31–35 on long-term potentiation in rat hippocampus is N-methyl-D-aspartate receptor-independent: it's offset by (-)-huperzine A. Neurosci Lett 1999; 275: 187–90.

  81. 81.

    , , . Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur J Pharmocol 2000; 398: 65–72.

  82. 82.

    , , . Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci Lett 2001; 313: 137–40.

  83. 83.

    , , , . Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxiaischemia. Brain Res 2002; 949: 162–70.

  84. 84.

    , , , , , et al. Elevated oxidative stress in models of normal brain aging and Alzheimer's disease. Life Sci 1999; 65: 1883–92.

  85. 85.

    . Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134–47.

  86. 86.

    , , , . Isolation of low-molecular-weight proteins form amyloid plaque fibers in Alzheimer's disease. J Neurochem 1986; 46: 1820–34.

  87. 87.

    , , . Antioxidant treatment in Alzheimer's disease: current state. J Mol Neurosci 2003; 21: 1–12.

  88. 88.

    , , . Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci Lett 1999; 275: 73–6.

  89. 89.

    , , , . Protective effects of huperzine Aon β-amyloid25–35 induced oxidative injury in rat pheochromocytoma cells. Neurosci Lett 2000; 286: 155–8.

  90. 90.

    , , . Huperzine A and tacrine attenuate β-amyloid peptide induced oxidative injury. J Neurosci Res 2000; 61: 564–9.

  91. 91.

    , , . Huperzine A attenuates amyloid β-peptide fragment 25–35–induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 2002; 67: 30–6.

  92. 92.

    , , . Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci Lett 2001; 306: 53–6.

  93. 93.

    , , . Improving effects of huperzine A on abnormal lipid peroxidation and superoxide dismutase in aged rats. Acta Pharmacol Sin 1999; 20: 824–8.

  94. 94.

    , , , , . Effects of huperzine A on [Ca2+]i level and expression of CaM, CaMPK II mRNA in hippocampal neurons of mice with vascular dementia. Clin J New Drugs Clin Rem 2004; 23: 73–6.

  95. 95.

    , . Apoptosis in the nervous system. Nature 2000; 407: 802–9.

  96. 96.

    , , . Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulation expression of apoptosis-related genes in rat PC 12 cells. Neuroreport 2001; 12: 2629–34.

  97. 97.

    , , . Huperzine A protects rat pheochromocytoma cells against oxygen-glucose deprivation. Neuroreport 2001; 12: 2073–7.

  98. 98.

    , . Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett 2002; 526: 21–5.

  99. 99.

    , . Huperzine A attenuates the neurotoxic effect of staurosporine in primary rat cortical neurons. Neurosci Lett 2003; 340: 91–4.

  100. 100.

    , . p53: puzzle and paradigm. Genes Dev 1996; 10: 1054–72.

  101. 101.

    , , . The permeability transition pore complex: another view. Biochimie 2000; 84: 153–66.

  102. 102.

    , , . Mitochondrial permeability transition: A common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 2003; 304: 463–70.

  103. 103.

    , , . Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 1998; 17: 37–49.

  104. 104.

    , . The mitochondrion in apoptosis: how Pandora's Box opens. Nat Rev Mol Cell Biol 2001; 2: 67–71.

  105. 105.

    , , , , , et al. Mediation of neuronal apoptosis by enhancement of outward potassium current. Science 1997; 278: 114–7.

  106. 106.

    , , , , . Enhancement of outward potassium current may participate in beta-amyloid peptide-induced cortical neuronal death. Neurobiol Dis 1998; 5: 81–8.

  107. 107.

    , , , , . Presenilins upregulate functional K+ channel currents in mammalian cells. Neurobiol Dis 1998; 4: 398–409.

  108. 108.

    , . Huperzine A, a nootropic agent, inhibits fast transient potassium current in rat dissociated hippocampal neurons. Neurosci Lett 2002; 324: 25–8.

  109. 109.

    , . Huperzine A inhibits the sustained potassium current in rat dissociated hippocampal neurons. Neurosci Lett 2002; 329: 153–6.

  110. 110.

    . Calcium and excitotoxic neuronal injury. Ann NY Acad Sci 1994; 747: 162–71.

  111. 111.

    . Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 1990; 13: 286–9.

  112. 112.

    , , . Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391–7.

  113. 113.

    . Glutamate-mediated injury in focal cerebral ischemia: the excitotoxin hypothesis revised. Brain Pathol 1994; 4: 23–36.

  114. 114.

    , , . Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004; 45: 583–95.

  115. 115.

    , . Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613–22.

  116. 116.

    . Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 1988; 11: 465–9.

  117. 117.

    . Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci 1995; 18: 58–60.

  118. 118.

    , , . The changing landscape of ischaemic brain injury mechanisms. Nature 1999; 399 Suppl 6738: A7–14.

  119. 119.

    , , , . Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984; 226: 850–2.

  120. 120.

    , , , , , et al. ZK200775: a phosphonate quinoxaline-dione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci USA 1998; 95: 10960–5.

  121. 121.

    , , , . Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. NeuroReport 1997; 8: 963–8.

  122. 122.

    , , , , , . The NMDA receptor ion channel: a site for binding of huperzine A. J Appl Toxicol 2001; 21 ( Suppl 1): S47–51.

  123. 123.

    , , , . Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Acta Pharmacol Sin 1999; 20: 31–5.

  124. 124.

    , . Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons. Neuroscience 2001; 105: 663–9.

  125. 125.

    , , , , , . Spermidine antagonizes the inhibitory effect of huperzine A on [3H]dizocilpine (MK-801) binding in synaptic membrane of rat cerebral cortex. Neurosci Lett 2002; 319: 107–10.

  126. 126.

    , , , , , . Similar potency of the enantiomers of huperzine A in inhibition of [(3) H]dizocilpine (MK-801) binding in rat cerebral cortex. Neurosci Lett 2000; 295: 116–8.

  127. 127.

    , , , , , et al. Cleavage of amyloid beta-peptide during constitutive processing of its precursor. Science 1990: 248: 1122–4.

  128. 128.

    , . Cellular processing of beta-amyloid precursor protein and the genesis of amyloid-beta peptide. Cell 1993; 75: 1039–42.

  129. 129.

    , , , , , et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J 1998; 12: 17–34.

  130. 130.

    , . Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism. Trends Pharmacol Sci 1999; 20: 418–23.

  131. 131.

    , , , . Release of Alzheimer amyloid precursor derivative stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304–7.

  132. 132.

    , , . The effect of cholinesterase inhibitors on the secretion of APPs from rat brain cortex. Ann NY Acad Sci 1996; 777: 393–8.

  133. 133.

    , , , . Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. NeuroReport 1995; 6: 633–6.

  134. 134.

    , , . Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-β in intracerebroventricular β-amyloid-(1–40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett 2004; 360: 21–4.

  135. 135.

    , , . Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative disease. Neurobiol Aging 1989; 10: 515–33.

  136. 136.

    , , . Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol 1989; 105: 221–32.

  137. 137.

    , , , , , . Potentiation of nerve growth factor-induced neurite outgrowth in PC 12 cells by a Coptidis Rhizoma extract and protoberine alkaloids. Biosci Biotech Biochem 2002; 66: 2491–4.

  138. 138.

    , . Cholinesterases in neural development: new findings and toxicologic implications. Environ Health Perspect 1999; 107 ( Suppl 1): 59–64.

  139. 139.

    , , . Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC 12 cells. Acta Pharmacol Sin 2005; 26: 673–8.

  140. 140.

    , , . Huperzine A protects SHSY5Y neuroblastoma cells against oxidative stress damage via nerve growth factor production. Eur J Pharmacol 2005; 519: 9–15.

  141. 141.

    , , , . Pharmacokinetics of huperzine A in rats and mice. Acta Pharmacol Sin 1988; 9: 193–6. Chinese.

  142. 142.

    , , , , , . Liquid chromatographic-tandem mass spectrometric method for the quantitation of huperzine A in dog plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 803: 375–8.

  143. 143.

    , , , . Ion-pair reverse-phase high performance liquid chromatography method for determination of huperzine-A in beagle dog serum. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 817: 187–91.

  144. 144.

    , , , , , . Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol Sin 1995; 16: 396–8.

  145. 145.

    , , , . Clinical pharmacokinetics of centrally acting cholinesterase inhibitors. In: , editors Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser; 1991. p 68–73.

  146. 146.

    , , , , . Indentification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of huperzine A. Eur J Pharmacol 2003; 461: 89–92.

  147. 147.

    , , , , . Effects of huperzine A on liver cytochrome P-450 in rats. Acta Pharmacol Sin 2003; 24: 831–5.

  148. 148.

    , , , , . Acute effects of huperzine A and tacrine on rat liver. Acta Pharmacol Sin 2003; 24: 247–50.

  149. 149.

    , , , , , . Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase. Pharmacol Biochem Behav 2005; 80: 53–61.

  150. 150.

    , , , . Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci 1994; 54: 991–7.

  151. 151.

    , , , , . Studies with huperzine A, a new candidate in the research of prophylaxis against nerve agent. In: editor Proceedings of the Medical Defence Bioscience Review 1996. p 105–10.

  152. 152.

    , , , , . Effects of huperzine used as pretreatment against soman-in-duced seizures. Neurotoxicology 2001; 24: 276–85.

  153. 153.

    , , , , , et al. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 2002; 23: 1–5.

  154. 154.

    , , , , , et al. Subchronic compared efficacy against soman toxicity. Drug Chem Toxicol 2002; 25: 309–20.

  155. 155.

    , , , , , . Efficacy of huperzine in preventing soman-in-duced seizures, neuropathological changes and lethality. Fund Clin Pharmacol 1997; 11: 387–94.

  156. 156.

    . Therapeutic effects of huperzine A on the aged with memory impairment. New Drugs Clin Remedies 1986; 5: 260–2. Chinese.

  157. 157.

    , , , , . Double-blind control treatment with huperzine A and placebo in 28 patients with Alzheimer disease. Clin J Pharmacoepidemiol 1995; 4: 196–8. Chinese.

  158. 158.

    , . Clinical report of huperzine A for the treatment of Alzheimer's disease. He Bei Jing Shen Wei Sheng 1996; 9: 84–5. Chinese.

  159. 159.

    , , , . Efficacy of tablet huperzine A on treating 21 patients with Alzheimer's disease. Si Chuan Jing Shen Wei Sheng 1996; 9: 204. Chinese.

  160. 160.

    , , , . Clinical observation of huperzine A on 36 patients with Alzheimer's disease. Nan Tong Yi Xue Yuan Xue Bao 1998; 18: 486–8. Chinese.

  161. 161.

    , , , . The clinical observation of Alzheimer's disease treated by huperzine A. Chin J Clin Phar 1998; 7: 270–2. Chinese.

  162. 162.

    , , , . Clinical observation of huperzine A on 36 patients with Alzheimer's disease. Shanghai Yi Yao 1999; 20: 16–8. Chinese.

  163. 163.

    , , , , , . Observation of aniracetam and huperzine on memory function of Alzheimer's disease. Modern Rehabil 2000; 4: 1622–3. Chinese.

  164. 164.

    , , . Improvement of huperzine A on the deficiency of cognitive and behavior in Alzheimer's disease. Clin Med China 2002; 18: 802–3. Chinese.

  165. 165.

    , . Clinical efficacy of huperzine A on Alzheimer disease. Chin J Clin Rehabil 2003; 7: 112. Chinese.

  166. 166.

    , , . Efficacy and reliability of huperzine A in mild and moderate Alzheimer's disease. Chin J Clin Rehabil 2003; 7: 4258–9. Chinese.

  167. 167.

    , , , . Clinical evaluation of huperzine A in improving intelligent disorder in patients with Alzheimer's disease. Chin J Clin Rehabil 2004; 8: 1216–7. Chinese.

  168. 168.

    , , , . Comparison of huperzine A in capsule and tablet on random, double-blind treating mild and moderate Alzheimer's disease. Shanghai Yi Yao 1999; 20: 36–7. Chinese.

  169. 169.

    , , , , , et al. Huperzine A capsules vs tablets in treatment of Alzheimer disease: multi-center studies. Chin J New Drugs Clin Remedies 2000; 19: 10–2. Chinese.

  170. 170.

    , , , , . Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Acta Pharmacol Sin 1999; 20: 601–3.

  171. 171.

    , , , , . Effectiveness of polydrug therapy for senile dementia. Chin J Clin Rehabil 2004; 8: 1214–5. Chinese.

  172. 172.

    , , , , , et al. Nilestriol combined with huperzine in improving cognition of female patients with Alzheimer's disease. Chin J Clin Rehabil 2003; 7: 1538–9. Chinese.

  173. 173.

    . Huperzine A assisted with the training of daily life promotes rehabilitation of Alzheimer's disease. Chin J Clin Rehabil 2002; 6: 2551. Chinese.

  174. 174.

    , , . Therapeutic effects of huperzine A complementing with 3R mental stimulation program in senile dementia patients. Chin J Clin Rehabil 2002; 6: 2560–1. Chinese.

  175. 175.

    , , , , , et al. Drug evaluation of huperzine A in the treatment of senile memory disorders. Acta Pharmacol Sin 1991; 12: 250–2. Chinese.

  176. 176.

    , . A self-control study of huperzine A on memory deficits in patients with multiple infarctions. Henan Yi Yao Xin Xi 1998; 6: 31–2. Chinese.

  177. 177.

    , , . A self-control study of huperzine A on memory deficits in patients with multiple infarctions. Zhong Yuan Jing Shen Yi Xue Xue Kan 1998; 4: 151–3. Chinese.

  178. 178.

    , , , . A study of the efficacy of huperzine A in the treatment of memory deficiency and recognition decline of cerebral organic disease. Sichuan Jing Shen Wei Sheng 2001; 14: 75–6. Chinese.

  179. 179.

    , , . The effects of huperzine A on vascular dementia. Modern Rehabil 2001; 5: 74–5. Chinese.

  180. 180.

    , , . Treatment on 20 cases of multi-infarct dementia with huperzine A. Yi Yao Dao Bao 2002; 21: 275–6. Chinese.

  181. 181.

    . Huperzine A vs pyritinol in treating dementia from multiple infarctions. New Drugs Clin Remedies 1997; 16: 333–4. Chinese.

  182. 182.

    , , , . A pilot trial of huperzine A on treating the cognitive deficiency in endemic cretinism. Shanxi Yi Yao Za Zhi 1995; 24: 47–8. Chinese.

  183. 183.

    , . Therapeutic effects of huperzine A on urinary incontinence after cerebral stroke. J Pract Nerv Dis 2004; 7: 77. Chinese.

  184. 184.

    , , , , , . A clinical study of the effect of huperzine A to improve the ability of verbal recall, retention and repetition in middle-aged and elderly patients with dysmnesia. Herald Med 2002; 21: 263–5. Chinese.

  185. 185.

    , , . Pilot trial of huperzine A to treat child language delay. J Pediatr Pharm 2002; 8: 26–7. Chinese.

  186. 186.

    , , . A clinical study of huperzine Aon mild and moderate traumatic brain injury in memory and cognitive impairment. Chin J Rehabil Med 2002; 17: 162–4. Chinese.

  187. 187.

    , , . Effect of huperzine A on the memory disorders of schizophrenic patients during rehabilitation period. Health Psychol J 2003; 11: 340–1. Chinese.

  188. 188.

    , , , . Effects of huperzine A on memory patients with schizophrenia. Shandong Jing Shen Yi Xue 2002; 15: 39–40. Chinese.

  189. 189.

    . The effects of huperzine A on the cognitive deficiency of rehabilitating schizophrenia. Chin J Clin Rehabil 2003; 7: 1440. Chinese.

  190. 190.

    , , . A clinical trial of day and night alternated administration of huperzine A and clonazepam to treat chronic insomnia. Chin J Nerv Ment Dis 2003; 29: 58–9. Chinese.

  191. 191.

    , . Effects of huperzine A tablet on memory. New Drugs Clin Remedies 1990; 9: 339–41. Chinese.

  192. 192.

    , , , . Oral administration of huperzine A improved memory disorder: a clinical study. Zhong Guo Xin Yao Za Zhi 1996; 5: 33–4. Chinese.

  193. 193.

    , , , , , . Double-blind and placebo controlled study of huperzine A on treatment of benign senescent forgetfulness. Chin J Geriatr 1996; 15: 180. Chinese.

  194. 194.

    , , . Comparison of the efficacy between tablet and capsule of huperzine to treat age associated memory impairment by double blind trial method. Zhong Guo Lin Chuang Yao Xue Za Zhi 1999; 8: 227–9. Chinese.

  195. 195.

    , . Huperzine A capsules vs tablets in treating senile amnesia: a double-blind study. Chin J New Drugs Clin Remedies 2000; 19: 33–5. Chinese.

  196. 196.

    , . Huperzine A capsule vs huperzine A in treatment of age-associated memory impairment with a double-blind study. Shandong Arch Psychiatr 2001; 14: 88–90. Chinese.

  197. 197.

    , , , , . Huperzine A capsule in treatment of age-associated memory impairment with a double-blind study. Sichuan Jing Shen Wei Sheng 2003; 16: 1–3. Chinese.

  198. 198.

    , , , , , . One hundred and twenty-eight cases of myasthenia gravis treated with huperzine A. New Drugs Clin Remedies 1986; 5: 197–9.

  199. 199.

    , . Clinical study of huperzine A on the treatment of myasthenia gravis. Proc J Med Pharm 2002; 19: 31. Chinese.

Download references

Author information

Affiliations

  1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China

    • Rui Wang
    • , Han Yan
    •  & Xi-can Tang

Authors

  1. Search for Rui Wang in:

  2. Search for Han Yan in:

  3. Search for Xi-can Tang in:

Corresponding author

Correspondence to Xi-can Tang.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1111/j.1745-7254.2006.00255.x

Further reading